Robert Canarick Adds to INBP Holdings
Robert Canarick purchased 50,000 shares of INBP on June 24, 2026.
Key Points
- Robert Canarick bought 50,000 shares of INBP on June 24, 2026, with shares trading at $0.18.
- Shares of INBP traded near $0.18 on Thursday, reflecting recent insider buying activity.
- Other insiders also bought 50,000 shares each on the same date, signaling interest in the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Robert Canarick made a move to increase his stake in INBP by purchasing 50,000 shares on June 24, 2026. The transaction took place without a specified purchase price, but shares of INBP traded around $0.18 on that Thursday.
Insider Buying and Selling at Integrated BioPharma, Inc.
In addition to Robert Canarick, several other insiders at INBP showed confidence in the company by buying shares on the same day. Desantis Damon, Friedman Eric, and Milmoe William each acquired 50,000 shares. These transactions were not part of any pre-planned trading programs. However, earlier in the year, on April 15, 2026, Milmoe William sold 11,201,964 shares, indicating a large divestment at that time.
Bottom Line
Insider buying often attracts investor attention as it can suggest confidence in the company's prospects. Robert Canarick's recent purchase of 50,000 shares of INBP adds to a series of similar buys by other insiders. While insider activity is one piece of the puzzle, it remains important to consider broader market conditions and company fundamentals when evaluating stock moves.
Get Integrated BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $INBP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.